

Eli Lilly Turns to Alchemab to Add Another AI-Discovered ALS Drug Prospect
Eli Lilly is licensing rights to a Phase 1-ready antibody that startup Alchemab developed for amyotrophic lateral sclerosis and other neurodegenerative disorders. Lilly’s pipeline has ALS drug candidates from previous deals with QurAlis and Verge Genomics.

How Healthcare Employers Can Do More To Help Providers Manage Payer Frustration
Health insurance claims are a growing headache for providers; many say their employers could do more to help them address the daily demands of insurers

A Reality Check on SDOH: Challenges We Can’t Ignore
A very small percentage of health outcomes are tied to direct healthcare activities. The non-medical factors, conditions in which people are born, grow, live, and work in, more often than not, impact health outcomes more than the clinical care they receive.

Eliminating Blind Spots in the Patient Journey
The webinar, scheduled for May 22, will include executives from PurpleLab and feature Genentech Principal Informatics Systems Lead Dr. Ben Freiberg. Register today!

What Is the Economic Impact of Medicaid Work Requirements?
Between 4.6 million and 5.2 million adults would lose Medicaid coverage in 2026 due to proposed work requirements, according to a new report.